Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
- First Posted Date
- 2004-01-13
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 695
- Registration Number
- NCT00075764
- Locations
- 🇺🇸
Grant Medical Center Cancer Care, Columbus, Ohio, United States
🇺🇸Mount Carmel Health - West Hospital, Columbus, Ohio, United States
🇺🇸Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-07-23
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 694
- Registration Number
- NCT00065325
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 148
- Registration Number
- NCT00057941
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer
- Conditions
- Locations
- 🇬🇧
Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom
ICI 182780 in Treating Women With Metastatic Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 80
- Registration Number
- NCT00012025
- Locations
- 🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇺🇸CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
🇺🇸Siouxland Hematology-Oncology, Sioux City, Iowa, United States
Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 67
- Registration Number
- NCT00006903
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.